AbbVie Inc.

New York Stock Exchange
Back to all articles
Bullish +65

AbbVie or Bristol-Myers Squibb: Better Healthcare Stock for 2026?

📊 AbbVie reported Fiscal Year 2025 revenues of $61.2 billion, an 8.6% increase driven by newer drug labels offsetting legacy product erosion.

💰 Bristol-Myers Squibb recorded a slight revenue decrease to $48.2 billion in FY 2025 but recovered net income to approximately $7.1 billion via one-time charges.

🧬 AbbVie is transitioning away from Humira dependence as biosimilar competition mostly passes, with its neuroscience portfolio accelerating growth.

⚠️ Bristol-Myers Squibb faces substantial revenue decline risks due to expected market exclusivity losses for blockbuster drugs Eliquis and Opdivo.

📈 AbbVie recently raised its full-year outlook for the second time this year, signaling strong operational momentum.

💸 Both companies offer consistent dividends and stable cash flows, making them attractive to income-seeking investors in the healthcare sector.

🏆 The author favors AbbVie over Bristol-Myers Squibb due to its focused strategy, faster growth rate, and higher dividend yield.

📉 Bristol-Myers Squibb trades at a lower Forward P/E ratio than AbbVie, reflecting market expectations of slower future growth.

⚖️ Both companies face industry-wide risks including patent expirations, competition from major rivals like Pfizer and Merck, and potential pricing pressures from the Inflation Reduction Act.

Bullish Signals
  • AbbVie achieved an impressive 8.6% revenue growth in FY 2025 to reach $61.2 billion, driven by the successful expansion of newer drug labels.
  • The company has successfully navigated the Humira patent cliff with biosimilar competition mostly past, allowing its neuroscience portfolio to accelerate growth.
  • AbbVie recently raised its full-year financial outlook for the second time this year, demonstrating strong management confidence and operational execution.
  • AbbVie offers one of the most enticing dividends in the healthcare sector, providing significant value to income-focused investors.
  • The company maintains a focused operation strategy that is delivering better results compared to peers with more diversified but slower-growing portfolios.
Risk Factors
  • AbbVie faces ongoing risks from patent expirations on key immunology drugs and rising competition in the specialty medicine market against rivals like Pfizer.
  • The company may be impacted by potential pricing pressures resulting from government regulations under the Inflation Reduction Act.
  • Bristol-Myers Squibb contends with global pricing and reimbursement restrictions that limit its pricing flexibility and could compress margins.
  • The company faces long-term growth risks if there are setbacks in clinical trials or regulatory delays for its next-generation pipeline products.
Full Analysis
This article presents a comparative investment analysis between pharmaceutical giants AbbVie (ABBV) and Bristol-Myers Squibb (BMY), evaluating their growth potential, financial performance, and risk profiles for investors targeting 2026. The author concludes that AbbVie is the superior pick due to its focused operational strategy, faster growth trajectory, and high-yielding dividend, positioning it as a stronger long-term investment compared to Bristol-Myers Squibb. AbbVie reported Fiscal Year 2025 revenues of approximately $61.2 billion, representing an 8.6% year-over-year increase driven by the expansion of newer drug labels that offset erosion from legacy products. The company is successfully transitioning away from its dependence on Humira as biosimilar competition subsides, with its neuroscience portfolio accelerating growth and prospects looking promising following the recent patent cliff for its flagship immunology drug. In contrast, Bristol-Myers Squibb saw a slight revenue decline of 0.2% to $48.2 billion in FY 2025, though it achieved a net income recovery of approximately $7.1 billion largely due to one-time charges. The company faces significant headwinds including expected market exclusivity losses for blockbuster drugs like Eliquis and Opdivo, global pricing restrictions, and dependence on new product launches to sustain growth in its oncology and cardiovascular segments. The analysis highlights that while Bristol-Myers Squibb trades at a lower Forward P/E ratio suggesting slower growth expectations, AbbVie offers more enticing value through its dividend yield and improved outlook. The author notes that AbbVie recently raised its full-year guidance for the second time this year, reinforcing its positive momentum despite broader industry challenges like drug pricing reforms under the Inflation Reduction Act.